(1) The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy's AI technology, applied to liver fibrosis characterization The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) NASH Regulatory News: Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for its proprietary imaging platform iBiopsy validation. The study is related to the iBiopsy NASH Clinical Development Plan (CDP).